Assertio Therapeutics (ASRT) Tops Q2 EPS by 1c

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $40.1 million versus the consensus estimate of $39.83 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Goldman starts Talen at buy, sees PJM power tightness boosting earnings
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight